Arabic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Rewilding the Human Gut: Reintroduction of the Species Lactobacillus Reuteri

يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
يتم حفظ الارتباط في الحافظة
الحالةمنجز
الرعاة
University of Alberta

الكلمات الدالة

نبذة مختصرة

Our guts are home to millions of microbes. These microbes help our bodies do important tasks like digesting food, fighting diseases and making vitamins. The type of microbes present in our gut depends on factors like diet, the use of medications, and sanitation practices. Research shows the diversity of the microbes living in our gut is decreasing, especially as countries become more developed. For example, stool samples from rural Papua New Guineans contain an additional 50 species not found in people living in the United States.
What has caused the disappearance of L. retueri is currently unknown. However, it is known that in order to help this species to grow specific types of carbohydrates need to be consumed. People in North America eat much less of these carbohydrates compared to rural Papua New Guineas. Examples of foods containing these carbohydrates include yams, beans, and artichokes. It may be possible for L. reuteri to live in the human gut if it is taken as a probiotic and a diet containing the types of foods which helps it grow is eaten. Furthermore, if L. reuteri can be re-established, it may have beneficial effects on how our immune system works.
The investigators hypothesize that L. Reuteri can be re-established in the gut of Canadians when they are fed a diet containing the types of foods known to help it grow. To test this hypothesize, the survival of two strains of L. Reuteri in the gut of Canadians will be compared when they eat their usual diet, to when they eat a diet containing the types of food known to help L. Reuteri survive. We will measure the amount of L. retueri present in stool samples of participants, and measure changes in metabolic and immune markers that occur as a result of the intervention. This study will help determine if a 'lost' species can be reintroduced into the human gut, and if this is associated with immune and metabolic health.

وصف

There is now substantial evidence that industrialization has resulted in substantial decrease in the bacterial diversity of the gut microbiota (Segata, 2015), likely due to a combination of factors such as use of antibiotics, modern clinical practices, sanitation, and change in dietary habits. However, the only factor for which empirical evidence is exists is the low content of Microbiota-Accessible Carbohydrates (MACs) in Western diets, which are indigestible dietary carbohydrates that become available to the microbes colonizing the intestine (Sonnerburg et al., 2015).

Previous work has confirmed the overall premise of 'microbiome depletion' by demonstrating higher diversity in the fecal microbiota of individuals from rural tribes in Papua New Guinea, which contain an additional of 50 species completely undetectable in North Americans (Martínez et al., 2015). One species detectable in every Papua New Guinean individual by 16S rRNA sequencing but not in a single US control was Lactobacillus reuteri (L. Reuteri). Interestingly, this species, which is also used as a probiotic, was regularly detected in humans in studies conducted around 1960 but is very rarely found in contemporary humans, suggesting a recent decline of the L. reuteri population in Westerners (Walter et al., 2011). Most importantly, L. reuteri is a member of the gut microbiota in many vertebrate species and exerts substantial benefits towards host immune functions and development, as demonstrated in a number of highly cited publications (Zelante et al. 2013; Buffington et al. 2016; Lamas et al. 2016; He et al. 2017).

It is currently unclear what caused the drop in the L. reuteri population. However, it is likely due to the importance of two dietary substrates, the carbohydrates raffinose and rhamnose, that are present at very low amounts in western diet, while being abundant in the diet of Papua New Guineans, a population that consumes a predominantly plant-based diet. Raffinose is a non-digestible oligosaccharide present in root vegetables, yams and beans, and it is an excellent growth substrate for L. reuteri. Rhamnose is a monosaccharide present in cell wall of many plants and can be fermented by enteric bacteria into 1,2-propanediol (1,2-PD), which facilitates the growth of L. reuteri in the presence of raffinose. Interestingly, L. reuteri strains isolated from Papua New Guniea fecal samples grow faster than the western strains MM4-1a and DSM2016T on both raffinose and raffinose+1,2-PD. This demonstrates that strains from Papua New Guinea are different from western isolates, likely due to adaptation to dietary substrates.

The goal of this study is to demonstrate that a bacterial species dominant in the non-westernized microbiome can be 'reintroduced' in the gut of Canadians fed a diet designed to promote the growth of the bacteria. This study will also determine how this 'reintroduction' influences immune function of the host and host-diet-microbiome metabolic interactions, and explore associations between them. The central hypothesis is that an isolate of L. reuteri, originating from rural Papua New Guinea, can be established in the gut of Canadians fed a diet containing the carbohydrates known to facilitate the growth of this microbe. It is also hypothesized that this 'reintroduction' with be associated with immunological and metabolic benefits to the host. To achieve these goals, the following aims are proposed:

1. To conduct a human trial to determine if a Lactobacillus reuteri strain isolated from rural Papua New Guinea (PNG) can be established in the gut of healthy Canadians.

2. To determine if colonization can be improved by feeding/promoting a diet specifically designed to provide growth substrates for L. reuteri.

3. To determine how both L. reuteri and the dietary intervention changes the human microbiome, metabolome, and immune biomarkers of inflammation.

This study will answer the important question if a 'lost species' can be reintroduced into the human gut, and provide potential mechanism how they may reduce the risk of chronic diseases. The availability of L. reuteri isolates from Papua New Guinea that are functionally different from western isolates in their growth on dietary components low in the western diet provides a unique opportunity to characterize strains from a beneficial bacterial species that were not exposed to modern lifestyle.

تواريخ

آخر التحقق: 04/30/2020
تم الإرسال لأول مرة: 11/20/2017
تم إرسال التسجيل المقدر: 04/08/2018
أول نشر: 04/17/2018
تم إرسال آخر تحديث: 05/03/2020
آخر تحديث تم نشره: 05/04/2020
تاريخ بدء الدراسة الفعلي: 02/20/2019
تاريخ الإنجاز الأساسي المقدر: 01/30/2020
التاريخ المتوقع لانتهاء الدراسة: 01/30/2020

حالة أو مرض

Microbial Colonization

التدخل / العلاج

Other: L Reuteri PB-W1 Strain

Other: L. Reuteri DSM20016T Strain

Other: Placebo

مرحلة

-

مجموعات الذراع

ذراعالتدخل / العلاج
Experimental: L. Reuteri PB-W1 Western Diet Start
5 participants will be assigned to this group and provided with a one time dose of L. Reuteri PB-W1 strain provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The L. Reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
Experimental: L. Reuteri DSM20016T Western Diet Start
5 participants will be assigned to this group and provided with a one time dose of L. Reuteri DSM20016T strain provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The L. Reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
Placebo Comparator: Placebo Western Diet Start
5 participants will be assigned to this group and provided with a one time dose of a placebo provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The placebo will be provided as a drinkable solution (approximately 2 g maltodextrain dissolved in 50 ml of water).
Experimental: L. Reuteri PB-W1 Non-Western Diet Start
5 participants will be assigned to this group and provided with a one time dose of L. Reuteri PB-W1 strain provided on day 4 of each diet period.The participants will be assigned to consume a non-western diet that will be prepared by the research team. The L. Reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
Experimental: L. Reuteri DSM20016T Non-West Diet Start
5 participants will be assigned to this group and provided with a one time dose of L. Reuteri DSM20016T strain provided on day 4 of each diet period. The participants will be assigned to consume a non-western diet that will be prepared by the research team. The L. Reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
Placebo Comparator: Placebo Non-Western Diet Start
5 participants will be assigned to this group and provided with a one time dose of a placebo provided on day 4 of each diet period. The participants will be assigned to consume a non-western diet that will be prepared by the research team. The placebo will be provided as a drinkable solution (approximately 2 g maltodextrain dissolved in 50 ml of water).

معايير الأهلية

الأعمار المؤهلة للدراسة 18 Years إلى 18 Years
الأجناس المؤهلة للدراسةAll
يقبل المتطوعين الأصحاءنعم
المعايير

Inclusion Criteria:

- Healthy and overweight individuals with a BMI between 20-29.9 kg/m²

- Preferably have one bowel movement per day

- Willing to consume prepared study foods (breakfast, lunch dinner, snacks) for a period of 3 weeks

- Men and pre-menopausal, non-pregnant or non-lactating women

- Non-vegetarian, non-smoking, and alcohol intake ≤8 drinks/week, and willing to consume 8 drinks per week or less during the course of the study.

- If consuming probiotic containing foods, willing to discontinue eating same, and substitute with non-probiotic containing foods

-≤5 h/week of moderate-vigorous exercise.

- Quantity of L. reuteri in screening fecal sample below 10^4 CFU/g

Exclusion Criteria:

- History of diabetes, acute or chronic GI illnesses, conditions, or history of GI surgical intervention

- antibiotic treatment in the last 3 months

- use of dietary supplements (including prebiotics and probiotics, fiber supplements/bars, digestive enzymes/beano)- if consumed, willing to undergo 4 week pre-intervention washout period, and remain free of supplements for duration of study. Exception: multivitamin or vitamin d supplement (1 week washout period)

- use of antihypertensive, lipid-lowering, anti-diabetic, anti-inflammatory (i.e corticosteroids or chronic NSAID use), or laxative medications

- known food allergies or intolerances (including dairy allergic or lactose intolerant)

النتيجة

مقاييس النتائج الأولية

1. Establishment of L. Reuteri (PB-W1 & DSM20016T strains) in the gut of Canadian individuals [8 days]

The primary outcome of this study is to determine if L. Reuteri PB-W1 strain can be established in the gut of Canadian individuals. This will be measured in stool samples by qPCR and culturing methods.

2. Colonization of L. Reuteri (PB-W1 & DSM20016T strains) pending consumption of diet designed to provide growth substrates for L. Reuteri [21 days]

We aim to determine if the survival of L. Reuteri in the gut of Canadian individuals is improved by feeding a diet specifically designed to provide growth substrates for L. Reuteri. This will be measured in stool samples by qPCR and culturing methods

مقاييس النتائج الثانوية

1. Fecal microbiotia composition changes following provision of L. reuteri strains. [8-21 days]

16SrRNA-sequencing and whole metagenome sequencing will performed to determine gut microbial community changes following provision of L. Reuteri.

2. Fecal microbiota composition changes following the provision of a diet designed to promote survival of L. Reuteri strains. [8-21 Days]

16SrRNA-sequencing and whole metagenome sequencing will performed to determine gut microbial community changes following provision of a diet designed to promote the growth of L. Reuteri.

3. Impact of L. reuteri strains on host immune response. [8 & 21 Days]

Host immune response will be measured in blood samples by quantifying IgA, selected cytokines, TNF-alpha, INF- gamma, regulatory T cells, and white blood cell phenotyping using flow cytometry. We also will measure IgA in fecal samples using an ELISA kit.

4. To characterize changes to the metabolome following provision of L. Reuteri strains. [8 & 21 Days]

Plasma metabolome L. Reuteri strain associated changes will be measured, specifically, molecules with known immunological functions such as short chain fatty acids and indole derivatives of tryptophan, and bile acids following the provision of the treatment. This will be measured via high performance chemical isotope labeling liquid chromatography mass spectrometry platform.

5. To characterize changes to the lipidome following provision of L. Reuteri strains. [8 & 21 Days]

Plasma lipidome L. Reuteri strain associated changes will be measuredl, specifically, molecules with known immunological functions such as short chain fatty acids. These will be measured via ultra-high pressure liquid chromatography quadrupole time of flight mass spectrometry.

6. L. Reuteri strain associated changes in blood cholesterol. [8 & 21 Days]

L. Reuteri strain specific changes in cholesterol (triglycerides, low density lipoprotein, high density lipoprotein), and C-reactive protein will be measured in blood samples.

7. L. Reuteri strain associated changes in insulin and fasting blood glucose. [8 & 21 Days]

L. Reuteri strain specific changes in insulin and fasting blood glucose will be measured in blood samples.

8. L. Reuteri strain associated changes in mood state [21 days]

L. reuteri strain specific changes in individual mood state as measured by the profile of mood states questionnaire.

9. L Reuteri strain associated immune response to inflammation (ex vivo) [Day 8 & 21]

Mononuclear cells will be isolated from whole blood on ficoll gradients and the ability of cells to respond to a bacterial challenge (L. reuteri and lipoplysaccharaide) will be determined ex vivo.

انضم إلى صفحتنا على الفيسبوك

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم

  • يعمل في 55 لغة
  • العلاجات العشبية مدعومة بالعلم
  • التعرف على الأعشاب بالصورة
  • خريطة GPS تفاعلية - ضع علامة على الأعشاب في الموقع (قريبًا)
  • اقرأ المنشورات العلمية المتعلقة ببحثك
  • البحث عن الأعشاب الطبية من آثارها
  • نظّم اهتماماتك وابقَ على اطلاع دائم بأبحاث الأخبار والتجارب السريرية وبراءات الاختراع

اكتب أحد الأعراض أو المرض واقرأ عن الأعشاب التي قد تساعد ، واكتب عشبًا واطلع على الأمراض والأعراض التي تستخدم ضدها.
* تستند جميع المعلومات إلى البحوث العلمية المنشورة

Google Play badgeApp Store badge